Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical ...
【INCB123667】進行性固形がん / 第I相験 / INCB123667 / CDK2阻害剤 | 国立がん研究センター中央病院 先端医療 ...
Novel CDK2 Inhibitor INCB123667 Shows Promise in Ovarian Cancer ...
Early results from INCB123667 in cyclin E1 overexpressing/CCNE1 ...
Study of INCB123667 in Subjects With Advanced Solid Tumors | Clinical ...
INCB123667 for Platinum-Resistant Ovarian Cancer · Recruiting ...
Study of INCB123667 in Subjects with Advanced Solid Tumors, Trial ID ...
临床CDK2抑制剂：选择性和有效性的趋势 | 「药时代靶点说」系列文章 - 知乎
临床CDK2抑制剂：选择性和有效性的趋势 | 「药时代靶点说」系列文章|肿瘤_新浪财经_新浪网
Cdk2 Inhibitor II | | TargetMol
Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials ...
INCB123667(INCB123667) - 药物靶点：CDK2_在研适应症：铂耐药性卵巢癌，晚期恶性实体瘤_专利_临床_研发
A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed ...
The Future of CDK Inhibitors: Beyond 4 and 6 - ASCO
Explore the clinical trial results achieved through exceptional ...
Incyte data on CDK2 inhibitor in ovarian cancer | Business News Today ...
Safety and preliminary efficacy from a phase 1 study of INCB123667, a ...
617MO Safety and tolerability of INCB123667, a selective CDK2 inhibitor ...
Discovery of INCB123667, a potent and selective cyclin-dependent kinase ...
974P First-in-human phase I dose finding study of INCB123667, a ...
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific ...
Abstract 1143: Development of a CDK2-selective small molecule inhibitor ...
Incyte的CDK2抑制剂INCB123667在晚期实体瘤（尤其是卵巢癌症）患者中显示出有希望的临床活性证据-动脉网
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic ...
【ASCO会议报道】卵巢癌-CDK2抑制剂INCB123667，在CCNE1过表达/扩增且铂类耐药和难治性卵巢癌患者中有效 - 知乎
High-Content Phenotypic Screen of a Focused TCAMS Drug Library ...
CDK1 inhibitors might work in MDS by reducing chromothripsis. | Jyoti ...
Incyte's CDK2 inhibitor for ovarian and endometrial cancers | Chris De ...
Cdk1/2 Inhibitor III | Cdk1/2 Inhibitor | MedChemExpress
INCB0123667 for Cancer Clinical Trial 2022 | Power
NU6140 is a Highly Selective Cyclin-Dependent Kinase 2 (Cdk2) Inhibitor ...
